Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Fangzhou Inc. ( (HK:6086) ) has shared an update.
Fangzhou Inc. has completed a placing of 45,181,000 existing shares at HK$3.32 per share to at least six independent investors, followed by a top-up subscription of an equal number of new shares by the vendor, resulting in the issuance of new shares representing about 3.26% of the enlarged share capital. The transaction raised net proceeds of approximately HK$144.3 million, of which around 90% will be deployed to accelerate development, infrastructure, talent recruitment, data capabilities and market rollout of its AI-powered chronic disease management platform, with the remaining 10% earmarked for working capital and general corporate purposes, strengthening Fangzhou’s growth trajectory in digital health and AI-enabled medical services.
The most recent analyst rating on (HK:6086) stock is a Hold with a HK$3.00 price target. To see the full list of analyst forecasts on Fangzhou Inc. stock, see the HK:6086 Stock Forecast page.
More about Fangzhou Inc.
Fangzhou Inc., listed in Hong Kong and incorporated in the Cayman Islands, operates in the healthcare technology space with a focus on AI-driven chronic disease management platforms that target underserved patient and physician segments.
Average Trading Volume: 16,993,805
Technical Sentiment Signal: Strong Sell
Current Market Cap: HK$3.66B
See more insights into 6086 stock on TipRanks’ Stock Analysis page.